Tokyo Women's Medical University – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 34
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: TE24B6DAF61EN
Leaflet:

Download PDF Leaflet

Tokyo Women's Medical University – Developmental Therapeutics Review – Q4 2010
Tokyo Women's Medical University – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Tokyo Women's Medical University – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Tokyo Women's Medical University – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Tokyo Women's Medical University human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Tokyo Women's Medical University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Tokyo Women's Medical University’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Tokyo Women's Medical University’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Tokyo Women's Medical University in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Tokyo Women's Medical University’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Tokyo Women's Medical University.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Tokyo Women's Medical University and identify potential opportunities in those areas.
Tokyo Women's Medical University Snapshot
Tokyo Women's Medical University Overview
Key Information
Key Facts
Tokyo Women's Medical University – Research and Development Overview
Key Therapeutic Areas
Tokyo Women's Medical University – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Tokyo Women's Medical University – Pipeline Products Glance
Tokyo Women's Medical University Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Tokyo Women's Medical University – Drug Profiles
aldesleukin + therapeutic autologous lymphocytes + zoledronic acid
  Product Description
  Mechanism of Action
  R&D Progress
aldesleukin + therapeutic autologous lymphocytes + zoledronic acid
  Product Description
  Mechanism of Action
  R&D Progress
aldesleukin + therapeutic autologous lymphocytes + zoledronic acid
  Product Description
  Mechanism of Action
  R&D Progress
aldesleukin + therapeutic autologous lymphocytes + zoledronic acid
  Product Description
  Mechanism of Action
  R&D Progress
HLA-A 2402 restricted A2691N peptide + D0006 peptide + F2861 peptide + montanide ISA-51
  Product Description
  Mechanism of Action
  R&D Progress
RNF43-721 + Montanide ISA 51 + S-1 + CPT-11
  Product Description
  Mechanism of Action
  R&D Progress
Ulinastatin
  Product Description
  Mechanism of Action
  R&D Progress
Wilms Tumor 1 Peptide Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Tokyo Women's Medical University – Pipeline Analysis
Tokyo Women's Medical University – Pipeline Products by Therapeutic Class
Tokyo Women's Medical University Pipeline Products By Target
Tokyo Women's Medical University – Pipeline Products by Route of Administration
Tokyo Women's Medical University – Pipeline Products by Molecule Type
Tokyo Women's Medical University – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 34

LIST OF TABLES

Tokyo Women's Medical University – Pipeline by Therapy Area and Indication, 2010
Tokyo Women's Medical University – Pipeline by Stage of Development, 2010
Tokyo Women's Medical University – Monotherapy Products in Pipeline, 2010
Tokyo Women's Medical University – Combination Treatment Modalities in Pipeline, 2010
Tokyo Women's Medical University - Phase II, 2010
Tokyo Women's Medical University - Phase I, 2010
Tokyo Women's Medical University - Pipeline By Therapeutic Class, 2010
Tokyo Women's Medical University - Pipeline By Target, 2010
Tokyo Women's Medical University – Pipeline By Route of Administration, 2010
Tokyo Women's Medical University – Pipeline By Molecule Type, 2010 31

LIST OF FIGURES

Tokyo Women's Medical University – Pipeline by Therapy Area and Indication, 2010
Tokyo Women's Medical University – Pipeline by Stage of Development, 2010
Tokyo Women's Medical University – Monotherapy Products in Pipeline, 2010
Tokyo Women's Medical University – Combination Treatment Modalities in Pipeline, 2010
Tokyo Women's Medical University – Pipeline By Therapeutic Class, 2010
Tokyo Women's Medical University - Pipeline By Target, 2010
Tokyo Women's Medical University – Pipeline By Route of Administration, 2010
Tokyo Women's Medical University – Pipeline By Molecule Type, 2010 31

Ask Your Question

Tokyo Women's Medical University – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: